Condition

Refractory AML clinical trials and research

• 7Clinical trials
• 8Countries

Newest Refractory AML clinical trials

All recruiting trials (7)

• Adapt NK cells for high-risk AML bridging to stem cell transplant

  This study tests an allogeneic NK cell infusion with a brief IL-2 boost in adults with relapsed or refractory AML to see if treatment can help prepare for a future stem cell transplant.

  Recruiting Phase 1/2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07591649

• Treatment of relapsed or refractory acute myeloid leukemia with a new drug combination

  This study is testing a new combination of drugs to see if it can help people with relapsed or refractory acute myeloid leukemia feel better and improve their treatment outcomes.

  Recruiting Phase 1 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06737523

• Using Avapritinib to treat relapsed or refractory pediatric CBF-AML with KIT mutation

  This study is testing if a new drug called avapritinib can help children with a specific type of leukemia that keeps coming back and has a certain mutation, to see if it works better than the treatments they currently have.

  Recruiting Phase 2 Children's Hospital of Soochow University · Hefei, Anhui and 11 other locations · NCT06316960

• Using CLL-1 CAR NK cells to treat relapsed or refractory acute myeloid leukemia

  This study is testing a new type of immune cell treatment for people with relapsed or hard-to-treat acute myeloid leukemia to see if it helps them feel better.

  Recruiting Phase 1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06307054

• Combining oral azacitidine with gilteritinib for treating relapsed FLT3-mutated acute myeloid leukemia

  This study is testing if adding an oral medication called azacitidine to gilteritinib can help adults with relapsed FLT3-mutated acute myeloid leukemia feel better and live longer.

  Recruiting at 3 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 19 other locations · NCT06022003

• Investigating Ziftomenib with Other Treatments for Acute Myeloid Leukemia

  This study is testing if a new drug called ziftomenib, when combined with other treatments, can help people with acute myeloid leukemia who have certain genetic mutations feel better and stay safe during treatment.

  Recruiting at 44 sites Phase 1 Kura Oncology, Inc. · Phoenix, Arizona and 43 other locations · NCT05735184

• Evaluating the safety and effectiveness of tuspetinib in patients with relapsed or refractory acute myeloid leukemia

  This study is testing a new drug called tuspetinib to see if it can safely help people with relapsed or hard-to-treat types of leukemia and related blood disorders.

  Recruiting at 10 sites Phase 1/2 Aptose Biosciences Inc. · Birmingham, Alabama and 33 other locations · NCT03850574

Related topics

Quick answers

How many Refractory AML clinical trials are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 8 countries. The most sites are in United States (3 trials), China (3 trials), Australia (1 trial), Germany (1 trial), New Zealand (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 2: 2, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →